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Abstract 
Background: SERPINA1 is the gene for alpha‑1 antitrypsin (AAT), an acute phase protein with anti‑protease and 
immunoregulatory activities. Mutations in SERPINA1 gene cause AAT deficiency and predispose individuals to early‑
onset emphysema and liver diseases. Expression of the SERPINA1 gene is regulated by different promoters and alter‑
native splicing events among non‑coding exons 1A, 1B and 1C.
Methods: We have developed three quantitative PCR (QT‑PCR) assays (1A, 1B and 1C). These assays were applied for 
the analysis of SERPINA1 alternative transcripts in: (1) 16 human tissues and (2) peripheral blood leukocytes from 33 
subjects with AAT mutations and 7 controls.
Results: Tissue‑specific expression was found for the SERPINA1 transcripts. The 1A transcripts were mainly expressed 
in leukocytes and lung tissue while those detected with the 1B assay were highly restricted to leukocytes. Only 1B 
transcripts significantly correlated with serum AAT levels. The 1C transcripts were specifically found in lung, liver, kid‑
ney and pancreas. Furthermore, the expression of transcripts was related to AAT genotypes. While deficient variants of 
AAT had no pronounced effect on the transcript expression, null alleles were associated with significant reduction of 
different transcripts.
Conclusions: The possibility to discriminate between SERPINA1 alternative splicing products will help us to under‑
stand better the regulation of SERPINA1 gene and its association with SERPINA1 mutations‑related diseases.
Keywords: Alpha‑1 antitrypsin, Alpha‑1 antitrypsin deficiency, SERPINA1, Transcription, Alternative splicing, 
Quantitative PCR
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Background
Human alpha-1 antitrypsin (AAT), also named alpha-1 
proteinase inhibitor (α1-Pi) is the prototypic member 
of the serine protease inhibitor (SERPIN) superfamily 
of proteins [1]. AAT is codified by the SERPINA1 gene, 
which is located on human chromosome 14q32 [2–4], 
mapped in the same cluster together with other serpin 
genes, SERPINA3 (α1-antichymotrypsin), SERPINA4 
(kallistatin precursor), SERPINA5 (PCI, protein C inhibi-
tor), SERPINA9 (centerin), SERPINA10 (ZPI, protein 
Z-dependent protease inhibitor) as well as SERPINA11 
[5]. SERPINA genes have similarities in their structure 
and characteristically consist of four exons with identi-
cal positioning and phasing of the intron–exon bounda-
ries. Interestingly, in spite of their close proximity, the 
corresponding proteins have different functions, raising 
important questions about the evolution of gene function 
and expression.
The structure of SERPINA1 is organized into three 
non-coding exons (1A, 1B and 1C), four coding exons 
(2–5) and six introns [2–4]. Expression of the SERPINA1 
gene is controlled predominantly by two promoters in 
the 5′ untranslated region (5′UTR) regulatory region. The 
hepatocyte SERPINA1 promoter is located upstream of 
the hepatocyte transcription start site, within exon 1C [4, 
6, 7]. An alternative promoter region, located upstream 
of exon 1A, controls SERPINA1 expression in other cells, 
Open Access
*Correspondence:  bmartinezd@isciii.es 
1 Molecular Genetics Unit, Instituto de Investigación de 
Enfermedades Raras (IIER), Instituto de Salud Carlos III (ISCIII), Carretera 
Majadahonda‑Pozuelo Km 2,200, 28220 Majadahonda, Madrid, Spain
Full list of author information is available at the end of the article
Page 2 of 11Matamala et al. J Transl Med  (2015) 13:211 
such as monocytes and macrophages [7]. Therefore, the 
primary transcript generated in hepatocytes is smaller 
than two other major transcripts generated from exons 
1A and 1B. At least two different transcription start sites 
are located within the exon 1A, typically used in mono-
cytes, whereas a third transcription site is located before 
exon 1B [8–10]. Additional transcription initiation sites 
for SERPINA1 gene expression were proposed for cor-
neal cells and A549 lung cell line [11–13].
The transfer of the genomic information from DNA to 
RNA to protein is a highly complex process due to the 
generation of alternative gene products from a single 
gene locus [14]. This latter can occur through transcrip-
tional or post-transcriptional (splicing) mechanisms [15]. 
Thus, almost all multi-exon human genes can generate 
multiple mRNA/transcript variants, which may encode 
isoforms having different biological functions [16, 17]. 
Studies on alternatively spliced isoforms suggested that 
changes in splicing are related to gene function and spe-
cific diseases [18, 19]. Although splicing is an abundant 
phenomenon [20], characterization of splicing isoforms 
has not been performed for many genes, including SER-
PINA1 gene.
In the SERPINA1 gene, different transcripts are pro-
duced due to the use of different transcription initiation 
sites, and within non-coding exons (1A, 1B and 1C) the 
alternative splicing events occurring in a stimulus- and 
cell-type specific manner [7, 8, 21]. These facts highlight 
the importance of the 5′UTR region for the regulation of 
AAT expression.
AAT is expressed mainly by hepatocytes [9] although 
other cell types, including monocytes, macrophages, 
intestinal epithelial cells or cornea, also express this pro-
tein [12, 22–25]. The level of plasma AAT is controlled 
by a pair of co-dominant alleles and more than 100 vari-
ants have been described in the SERPINA1 gene [26]. For 
clinical purposes AAT variants are classified into four 
major categories: normal, deficiency, null and dysfunc-
tional. The most common allele is M resulting in a nor-
mal concentration of functionally active protein. Reduced 
levels of the AAT protein are commonly associated with 
deficient S and Z alleles [27]. There are also other rare 
deficient variants of the gene and cases with null alleles 
where no protein is produced due to the nonsense, 
frameshift or splicing mutations leading to truncated 
proteins, unstable transcription or mRNA degradation. 
SERPINA1 gene produces several transcription prod-
ucts of putative clinical relevance. Therefore, it is of great 
interest to detect and quantify these products in differ-
ent tissues, and to explore the effect of genetic variants 
of SERPINA1 on transcription levels of the gene. Quan-
titative real-time reverse transcription-PCR was used 
before to study SERPINA1 expression under different 
experimental conditions and to assess the effect of gene 
mutations on transcription [28, 29]. However, the quanti-
fication of the different SERPINA1 splicing isoforms has 
not been performed to date. Therefore, the development 
of methods to quantify the abundance of these isoforms, 
and the characterization of the splicing pattern in differ-
ent tissues remains of great importance.
Quantitative real-time PCR (QT-PCR) is a “gold” 
standard for mRNA quantification and has occasionally 
been used for quantification of specific splicing isoforms 
[19, 30–33]. The aim of this study was to develop a QT-
PCR approach for measuring the expression level of the 
alternative transcripts of the SERPINA1 gene. Three 
different QT-PCR assays directed to non-coding exons 
1A, 1B and 1C were designed allowing quantification 
of specific transcripts. In order to evaluate the clinical 
relevance of alternative splicing isoforms, the expres-
sion of these transcripts was assessed in a set of different 
human tissue samples and in the peripheral blood sam-




Commercially available cDNA from human tissues 
(Human MTC Panel I and II, Clontech) were used to 
measure the expression of SERPINA1 transcripts in a 
total of 16 different human tissues including heart, brain, 
placenta, lung, liver, skeletal muscle, kidney, pancreas, 
colon, ovary, peripheral leukocytes, prostate, small intes-
tine, spleen, thymus. Two or more different experiments 
were performed in triplicate for all tissues. Expression in 
tissues was normalized to the expression obtained in a 
peripheral leukocyte sample.
AAT deficiency subjects samples
Peripheral blood samples were obtained from 33 AATD 
subjects evaluated in the Spanish Registry of Patients 
with AAT Deficiency or in the Center for Diagnosis of 
Inherited Alpha-1 Antitrypsin Deficiency in Pavia, Italy, 
and seven healthy individuals with normal (MM) AAT 
genotype that were used as controls. All cases had pre-
viously been genotyped by sequencing of all coding 
exons to characterize the mutation present in each case. 
Signed informed consent for the study was obtained 
from all the subjects and the study was approved by the 
ethics committee of Instituto de Salud Carlos III. Cases 
with deficient genotypes were members of a total of 18 
families carrying the common deficiency variants (S and 
Z), the rare deficiency variants MMalton and MProcida 
or the null alleles QOMattawa, QOPorto, QOMadrid, 
QOBrescia or MVarallo, in heterozygous or homozy-
gous state (Table  1). Among carriers of mutations, 20 
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presented with lung disease and 13 were asymptomatic 
blood relatives identified by family screening.
AAT serum levels were previously determined by 
nephelometry. Genotypes and serum AAT levels are 
described in Table 1.
RT‑PCR to analyze alternatively spliced products
Expression of different transcripts in tissues and periph-
eral blood white cells was evaluated by conventional 
reverse transcription polymerase chain reaction ampli-
fication (RT-PCR). Total RNA extraction was per-
formed using RNAeasy kit (Qiagen, Hilden, Germany). 
Afterwards, cDNA synthesis was carried out by reverse 
transcription using the Maxima First Strand cDNA Syn-
thesis kit (Thermo Scientific, Fermentas Life Sciences, St. 
Leon-Rot, Germany). Since alternative splicing can occur 
within non-coding exons (1A, 1B and 1C) generating 
different transcription products, in order to amplify the 
region between 1A-E2, 1B-E2 and 1C-E2, we used previ-
ously designed forward primers located in exons 1A, 1B, 
and 1C as well as a reverse primer in exon 2 [28]. PCR 
was performed on 1 μl of cDNA template and 100 ng of 
each primer. The amplification conditions were as fol-
lows: 35 cycles of denaturation at 94°C for 45 s, anneal-
ing at 60°C for 30 s, and extension at 72°C for 30 s. PCR 
products were separated by electrophoresis and visual-
ized on gel-red stained 2% agarose gels.
Quantitative PCR (QT‑PCR) of SERPINA1 transcripts
We quantitatively analyzed the expression of transcripts 
containing exon 1A, 1B or 1C. Three different assays (1A, 
1B and 1C) were defined (Figure 1; Additional file 1). For 
each assay specific primers were designed to amplify 
regions 1A-E2, 1C-E2 and 1B-1C, and specific fluores-
cent labelled Taqman probes were selected (Universal 
probe library, UPL, Roche) (Figure  1a). To specifically 
amplify transcripts with the 1A-E2 junction, a bound-
ary-spanning primer for the sequence encompassing 
the exon 1A to exon 2 junction (1Ae2_F:5′TGAGGAGA
GCAGGAAAGGACA3′) and a reverse primer in exon 
2 (1Ae2_R:5′CTCAGCCAGGGAGACAGG3′) together 
with the probe #18, were used. Thus, with the 1A assay 
we detected expression of transcript I (Figure 1b).
Assay 1C was designed to amplify a region between exon 
1C and exon 2. Junction between exon 1C to E2 is present 
in different transcription products and therefore it was 
not possible to design primers able to distinguish between 
splicing isoforms containing this region (Figure  1b). For 
this assay primers 1Ce2F: 5′ TTAAATACGGACGAGG 
ACAGG 3′ and 1Ce2R: 5′ACGAGACAGAAGACGG 
CATT3′, and the probe #73 were used. Another quantita-
tive assay was designed to measure the expression of tran-
scripts specifically containing exon 1B and 1C junction, 
using a forward primer in 1B (1B1C_F:5′CAGCTAAGTG
GTACTCTCCCAGA3′) and a reverse primer in 1C exon 
(1B1C_R:5′TCGTCCGTATTTAAGCAGTGG3′) in com-
bination with the probe #39.
The cDNA samples from patients and normal cases 
were diluted and amplified using Taqman Fast advance 
Table 1 Genotype and AAT serum levels of the cases ana-
lyzed




1 14S20 MM 133 Healthy control
2 12OCT02 MM 185 Healthy control
3 12OCT03 MM 124 Healthy control
4 12OCT05 MM 120 Healthy control
5 12OCT07 MM 132 Healthy control
6 12OCT08 MM 170 Healthy control
7 GM1 MM 102 Healthy control
8 12S01 MZ 70 Lung disease
9 12OCT01 ZZ 18 Lung disease
10 12OCT04 ZZ 23.6 Lung disease
11 12OCT06 ZZ 38 Lung disease
12 12OCT09 ZZ 11.5 Lung disease
13 14S19 ZZ 20 Lung disease
14 14S31 ZZ 16.1 Lung disease
15 13S09 M/MMalton 63.2 Lung disease
16 13S12 M/MMalton 75.9 Lung disease
17 13S13 M/MMalton 84.7 Family screening
18 14S27 M/MMalton 70 Family screening
19 14S28 M/MMalton 74 Family screening
20 14S30 M/MMalton 76 Family screening
21 14S29 MMalton/MMalton 6 Lung disease
22 13S03 S/MMalton 67.2 Lung disease
23 13S14 Z/MMalton 45 Lung disease
24 14S23 MProcida/MProcida 17 Lung disease
25 14S25 S/MProcida 49 Family screening
26 14S34 S/MProcida 70 Family screening
27 14S24 M/MProcida 69 Lung disease
28 14S35 M/MProcida 83 Family screening
29 14S36 M/MProcida 81 Family screening
30 14S37 M/MProcida 70 Family Screening
31 13S05 M/QOPorto 72 Family screening
32 13S06 M/QOPorto 67 Family screening
33 13S17 M/QOPorto 65 Family screening
34 13S07 QOPorto/QOMadrid 8.7 Family screening
35 13S08 QOPorto/QOMadrid 9 Lung disease
36 13S16 QOPorto/MProcida 33.4 Lung disease
37 13S02 M/QOMattawa 73.7 Lung disease
38 15S42 QOBrescia/QOBrescia <10 Lung disease
39 15S43 QOBrescia/QOBrescia <10 Lung disease
40 15S44 Z/Mvarallo <10 Lung disease
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master mix in a 7500 Fast Real Time PCR System 
(Applied Biosystems) with recommended PCR cycle 
conditions. Two genes (ACTB and GUSB) were used as 
endogenous controls to normalize the expression lev-
els of SERPINA1 transcripts. All experiments were per-
formed in triplicate and data were managed using the 
Applied Biosystems 7500 software v2.0. Relative expres-
sion was calculated by using the comparative Ct method 
and obtaining the fold-change value (ΔΔCt). The ΔCt 
value of each sample was calculated using ACTB and 
GUSB, as an endogenous control genes. An inter-plate 
calibration sample was used to compare samples ana-
lyzed in different PCR plates.
Statistical analysis
Kolmogorov–Smirnov test was used to analyze the nor-
mal distribution of the data and bilateral t test was applied 
using SPSS version 22 (SPSS Inc, Chicago, IL, USA). Nom-
inal two-sided p values <0.05 were considered statistically 
significant. Correlation between expression levels of 1A, 
1B and 1C and serum levels of AAT were estimated by 
Pearson’s coefficient. P values below 0.05 were considered 
as statistically significant.
Results
QT‑PCR assays for detection of alternative spliced 
SERPINA1 isoforms
To quantify specific splicing transcripts of the SERPINA1 
gene we developed a novel QT-PCR method (Figure  1). 
For this purpose exon–exon boundary spanning primer 
and primers located in alternative spliced exons 1B and 
1C were designed. Figure 1b shows the different splicing 
transcripts that are detected using each of the QT-PCR 
assays (1A, 1B and 1C).
Figure 1 Representation of SERPINA1 gene and QT‑PCR assays. a Schematic representation of the SERPINA1 gene exons with non‑coding exons 
(1A, 1B and 1C) and exons 2–5 coding for the AAT protein. Numbers above the non‑coding and coding exons represent the intron length in bp. 
Locations of the different primers used for the three QT‑PCR assays were represented by arrows. b Different alternative transcripts occur in the AAT 
gene by alternatively splicing of the non‑coding exons 1A, 1B and 1C and the use of the different transcription start sites. Five transcripts (I, II, III, IV 
and V) can be detected with any of the assays (1A, 1B and 1C). The exon structure of these transcripts corresponds to isoforms found in Ensembl 
database listed in the Figure. Additionally, another transcript structure (IV), generated by transcription from exon 1B, is not represented in Ensembl 
database but transcription from exon 1B have been described in the literature [8–10].
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Only transcript I contains the exon 1A directly joined 
to exon 2. Therefore, we employed a simple strategy using 
a primer spanning the exon 1A to exon 2 junction, and 
as illustrated in Figure 1b, the 1A assay specifically quan-
tifies the expression of transcript I. On the other hand, 
the boundary between exon 1C and exon 2 is not specific 
and it is included in several transcript variants (II, III, IV 
and V), which makes impossible individual quantification 
of transcripts containing this region. Therefore, the 1C 
assay amplifies and simultaneously detects several tran-
scripts II, III, IV and V. Similarly, the 1B assay, which is 
developed to detect and quantify the boundary between 
exon 1B and exon 1C, allows only the combined quantifi-
cation of transcripts III and IV (Figure 1b).
Pattern of expression of SERPINA1 isoforms in human 
tissues
The expression levels of different SERPINA1 transcripts 
were measured in a panel of various human tissues. 
Compared to other tissues, leukocytes showed a high-
est expression of the 1A, 1B and 1C transcripts (Fig-
ure 2). The transcript I, specifically detected with the 1A 
assay, was mainly expressed in leukocytes and lung tissue 
but it was also detected in liver, colon, spleen, prostate, 
kidney or brain at much lower level (Figure 2). In addi-
tion to leukocytes, 1C transcripts were also expressed 
in lung, liver and kidney and less abundantly expressed 
in pancreas and small intestine (Figure  2). The expres-
sion of transcripts detected by using 1B assay was almost 
exclusively restricted to leukocytes, although low expres-
sion was also found in lung and spleen. The commercial 
cDNA samples represent a pooled preparation from 
many individuals, therefore it is not possible to know 
which specific cell in the tissue samples is expressing the 
AAT transcripts. Further experiments using isolated cells 
remain to be performed.
SERPINA1 expression in leukocytes from peripheral blood 
by RT‑PCR
White blood cells isolated from peripheral blood samples 
were used to analyze SERPINA1 expression. Since alter-
native splicing occurs between exons 1A, 1B and 1C, we 
used forward primers located in these exons and anti-
sense primers in exon 2 (Figure 3). We previously found 
a unique expression fragment [28] corresponding to a 
transcript, in which the exon 1A is directly spliced to join 
exon 2 by skipping of the exons 1B and 1C (Figure  3b). 
This transcript was initiated in any of the two tran-
scription sites described within exon 1A [7]. However, 
with the primer located in exon 1B, several transcrip-
tion products of different size were observed, reflect-
ing the use of the different splicing sites located within 
exons 1B and 1C (Figure 3c). These products most likely 
begun in the initiation site described within exon 1B [7] 
since no alternative transcripts including exon 1B or 1C 
were detected using the primer in exon 1A. Finally, as 
expected, amplification using primer in exon 1C gener-
ated only one fragment corresponding to joined exon 
1C to exon 2 (Figure  3d). This region is present in all 
transcripts containing the exon 1C. Hence, we cannot 
determine whether its expression derived from the tran-
scription site within exon 1C or within exons 1A and 1B. 
Since our analysis was performed on white blood cells, 
this region most likely corresponds to transcripts starting 
Figure 2 Transcription analyses of SERPINA1 transcripts in human tissues. Relative expression levels of 1A, 1B and 1C transcripts in 16 human 
tissues is shown. Specific patterns of transcript expression were detected in different tissues. Leukocytes exhibited higher expression levels of 
transcripts 1A, 1B, and 1C when compared to other tissues. The 1A transcript was found predominantly in leukocytes and lung tissue. Specific 
expression of 1C transcripts were detected in lung, liver, kidney or pancreas, suggesting that transcription in these tissues start in the transcription 
site located in exon 1C. Expression of 1B transcripts were almost exclusively detected in leukocytes.
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at any of the monocyte transcription sites. Therefore, we 
think that leukocytes have active 1A and 1B transcription 
start sites.
Effect of SERPINA1 mutations on alternative transcripts 
expression
Three QT-PCR assays (1A, 1B and 1C, Figure  1) were 
applied on the peripheral blood samples from 33 AAT 
deficient subjects and 7 controls with normal MM 
genotype of AAT (Figure  4a). Subjects were carriers of 
heterozygous or homozygous variants of AAT (Z, S, 
MMalton, MProcida) or specific null alleles (QOMat-
tawa, QOPorto, QOMadrid, QOBrescia or MVarallo) 
(Table  1). Notably, controls showed similar expression 
levels of transcripts detected either by 1A, 1B and 1C 
assays, although expression of the transcript I, detected 
by the 1A assay, was slightly higher as compared to 1B 
and 1C transcripts (Figure 4b). When compared to con-
trols, ZZ patients showed no difference in the transcript 
levels. Interestingly, the level of 1A transcript appeared 
higher in cases carrying either one or two deficient AAT 
alleles (Figure 4b), and even higher in null cases caused 
by the splicing mutations but not by stop gain mutations 
(Figure  4a). Nevertheless, most cases with deficient 
alleles, such as heterozygous MMalton or MProcida 
alone or in combination with S or Z alleles, showed no 
significant changes in expression of the 1B and 1C tran-
scripts (Figure 4b). This supports the notion that Z and 
other deficiency mutations do not affect the transcrip-
tion of AAT. However, when compared to MM controls, 
null cases showed reduced levels of transcripts. Tran-
scripts 1B and 1C were significantly reduced in carriers 
of either one or two null alleles with splicing mutations 
(QOPorto and QOMadrid) affecting the splicing donor 
site of intron 1C. In two cases carrying these two splic-
ing mutations affecting both alleles, 1C transcripts were 
almost completely absent (Figure 4a). Null alleles caused 
by stop-gain mutations (QOMattawa and QOBrescia) 
showed substantial decrease in all transcripts. However, 
the null allele Mvarallo in combination with Z did not 
display any change in transcript levels.
Correlation between expression of different transcripts 
and they association with AAT protein levels
The expression of transcripts detected with 1B and 
1C assays showed a significant correlation (r  =  0.83, 
a
b c d
Figure 3 Representative expression of alternative transcripts in blood samples detected by RT‑PCR. a Schematic graphic of the structure of the 
SERPINA1 gene. Primers used for RT‑PCR expression analysis are represented by arrows. RT‑PCR expression analysis in leukocytes from peripheral 
blood samples showed evidence for different alternative splicing event occurring within noncoding exons 1A, 1B and 1C of SERPINA1 gene. b 
Amplification fragment corresponding to the expression in blood samples detected using a forward primer in exon 1A and a reverse primer in exon 
2. A single band of 633 bp was detected which corresponded to a transcript containing exon 1A joined directly to exon 2. c Bands detected by 
using forward primer 1B. Different expression fragments were detected corresponding to splicing variants. The structure of these splicing variants 
has been described in detail before [28]. Three different bands are clearly visualized due to the different splicing sites used within exons 1B and 1C. 
The band of 712 bp corresponded to the exon 1B joined to exon 2. The band of 816 bp corresponded to an isoform containing both exons 1B and 
1C. The upper band of 971 corresponds to a fragment with retained intron in between exons 1B and 1C. d Using a forward primer in the exon 1C a 
single band of 587 bp was amplified.
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p  <  0.0001) in all analyzed cases. This finding suggests 
that (1) both assays are detecting the same transcription 
products and (2) the expression detected with the 1C 
assay comes from the monocyte transcription initiation 
sites but not from the hepatocyte specific transcript initi-
ating in 1C exon. In contrast, the expression of 1B and 1C 
transcripts did not correlate with the different human tis-
sues analyzed, indicating that the 1C expression, at least 
in lung, liver, kidney or pancreas tissues (Figure 2) comes 
from the hepatocyte transcription start site. The expres-
sion of 1A transcript did not correlate with 1B (r = 0.27, 
p = 0.104) or 1C (r = 0.25, p = 0.138) expression. Nota-
bly, in peripheral blood cells the 1A transcript was 
expressed at a higher level than 1B and 1C transcripts.
In all subjects we found no significant correlation 
between serum levels of AAT protein and mRNA of AAT 
by using 1A or 1C assays. In the other hand, AAT mRNA 
detected by the 1B assay showed a weak correlation with 
serum levels of AAT protein (r  =  0.34, p  =  0.04) (Fig-
ure  5). When 1B assay was applied for cases with defi-
cient AAT alleles, levels of mRNA well correlated with 
serum AAT levels (r = 0.50, p = 0.016). Notably, this cor-
relation did not exist in null cases.
Discussion
Splicing variants have not yet been characterized for 
many genes and the contribution of most splicing events 
to human diseases, including AAT deficiency, remains 
unclear. The involvement of alternative splicing events in 
diagnosis and disease prognosis becoming increasingly 
recognized [17, 18]. This demands development of new 
methods to quantify the abundance of these isoforms 
Figure 4 Transcriptional analyses in cases with normal, deficient or null alleles. a Relative expression of the AAT transcripts detected with the 1A, 1B 
or 1C assays in blood samples of subjects with AAT deficiency with deficient or null variants and normal samples (MM). b Box plots of the levels of 
expression of the 1A, 1B and 1C transcripts in groups of normal cases (MM), ZZ patients, cases with one or two deficient alleles other than Z (DEF), 
and cases with null alleles (NULL). Median expression is represented by the horizontal line within the box. Cases with null alleles showed statistically 
significant differences (asterisk) in the expression of 1B and 1C transcripts compared with expression in MM cases.
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in clinical samples. The QT-PCR is a “gold” standard 
method to analyze splicing variants; however it is limited 
by the difficulties in designing primers specific to splicing 
isoforms [30, 34, 35].
We have developed a new QT-PCR method, which 
allows analysis of the expression of different SERPINA1 
transcripts generated by the alternative splicing between 
non coding exons 1A, 1B and 1C of the gene. Three QT-
PCR assays were designed by using primers spanning 
the exon–exon junction (assay 1A) or primers flank-
ing the alternatively spliced regions (assays 1B and 1C). 
Since some of the AAT noncoding exons are part of dif-
ferent transcript isoforms, separate quantification was 
only possible for transcripts with exon 1A joined to exon 
2 (transcript I, Figure 1b). Nevertheless, we were able to 
estimate the abundance of transcripts containing differ-
ent combinations of exons 1B or 1C.
The regulation of the expression of the SERPINA1 
gene is complicated because of the existence of two dif-
ferent promoter regions with several transcription start 
sites and the phenomenon of alternative splicing, lead-
ing to the potential production of different SERPINA1 
transcription products. At present 19 splice variants of 
the SERPINA1 are described in the Emsembl Genome 
Browser. Despite this large number of transcripts, only 
five of them represent main isoforms containing all cod-
ing exons and 3′UTR sequence with different combina-
tions of non-coding 1A, 1B and 1C exons.
So far, the expression of SERPINA1 gene has been ana-
lyzed without taking into account different transcription 
products of the gene. Therefore, the role of the different 
mRNA SERPINA1 products in different cell types and 
tissues remains to be established. The analysis of differ-
ent transcription products using our developed QT-PCR 
Figure 5 Correlation between expression level of transcripts and serum AAT levels in AAT deficient cases. Panels show correlation of expression 
of 1B transcripts (upper row), 1A (middle row) or 1C transcripts (lower row) with AAT levels in serum. Significant correlation was only found for 1B 
assay expression, both when all cases were analyzed together and in cases with deficient alleles, but not in cases with null alleles. ns Not statistically 
significant.
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assays, permitted elucidation of the specific pattern of 
SERPINA1 transcripts in different tissues. The QT-PCR 
results revealed that transcripts containing exons 1B and 
1C (transcripts III and IV, Figure 1b) are highly restricted 
to leukocytes. However, transcript containing exon 
1A bond to exon 2 (transcript I), although expressed at 
high level in leukocytes, was also detected in lung tissue 
and less abundantly in liver, spleen, colon and prostate. 
Hence, the monocyte transcription start sites located 
within exon 1A seems to be active in other tissues. Nev-
ertheless, currently we cannot dismiss the possibility that 
this expression comes from monocytes/macrophages 
present in the specific tissue.
Expression of different transcripts in lung, liver, kid-
ney, pancreas, spleen, colon, small intestine and pros-
tate detected by the 1C assay was higher than detected 
by 1A and 1B assays. We believe that the 1C expression 
in these tissues reflects the expression of transcript V ini-
tiated in the hepatocyte transcription start site. Indeed, 
transcripts from 1C might be specifically expressed in 
extra-hepatic tissues. In fact, this was previously reported 
in transgenic mice studies [36–38]. Further studies in iso-
lated cell types are warranted to elucidate the biological 
role of these different transcripts.
Furthermore, we found changes in the expression of spe-
cific transcripts in blood samples from subjects with AAT 
deficiency variants. As a matter of fact, null alleles pro-
duced by premature stop codons showed reduced levels of 
all transcripts. This latter could be explained by the activa-
tion of the nonsense mediated decay (NMD) mechanism 
typically occurring in null cases [39, 40]. This was specifi-
cally found in homozygous QOBrescia/QOBrescia cases 
and even in the M/QOMattawa. In null alleles caused by 
splicing mutations (QOPorto and QOMadrid) the reduc-
tion in 1B and 1C transcript levels might be explained 
by the fact that these splicing variants are localized in 
the donor splice site of exon 1C. It is probable that other 
null alleles, typically produced by premature stop codons, 
may have reduced levels of transcription. Supporting 
this assumption some researchers have found important 
effects of different AAT null mutations on the AAT mRNA 
level, such as QOGranite falls or QOTrastevere [41]. In 
general, cellular content of AAT mRNA is assumed to be 
affected by the distance of the nonsense codon from the 
initiator codon, although elements within the coding 
region may also have importance in conferring mRNA 
stability. Because transcription depends on the mutation, 
it is important to investigate whether other AAT variants 
(deficient and null) affect 1A, 1B or 1C transcription levels. 
Our QT-PCR approach might help to identify how muta-
tions affect transcription of the AAT gene.
Remarkably, subjects with deficient AAT alleles like 
Z, S, MMalton, and MProcida showed no significant 
differences in 1A, 1B or 1C transcription levels rela-
tive to normal MM cases. Pathogenesis of the deficient 
variants of AAT is typically characterized by intracellular 
accumulation of AAT and a concomitant reduction in its 
circulating levels but not by the reduction in protein syn-
thesis. Therefore, one cannot expect significant changes 
to occur at the mRNA level of the transcripts.
As AAT is an acute phase reactant, its expression 
increases during inflammatory responses. Although AAT 
is primarily synthesized in the liver [4], other cells also 
can produce lower amounts of AAT. Basal and modulated 
expression of AAT is controlled by many different cis and 
trans-acting factors that can substantially activate tran-
scription [7, 11, 42, 43]. The increased secretion of AAT 
is mainly mediated by the cytokines, such as IL-6, IL-1β, 
TNFα, oncostatin M or bacterial lipopolysaccharide [21, 
42, 43]. These stimuli seem to act specifically on hepato-
cytes, monocytes, macrophages or other AAT producing 
cells, and to induce expression of AAT by the different 
magnitude [29]. How all these factors affect expression, 
stability or translation rates of the different SERPINA1 
transcripts remains to be elucidated.
Conclusion
We developed three QT-PCR assays to quantify the 
expression of SERPINA1 transcripts. By using these 
assays we quantified specific expression of transcripts in 
various tissues and found that transcript expression is 
affected by the deficient and null variants of SERPINA1 
gene. The possibility to distinguish specific alternative 
transcripts opens new possibilities to explore the clinical 
importance of SERPINA1 gene mutations. Moreover, it 
helps to build a better understanding of regulation mech-
anisms of SERPINA1 gene expression. To understand the 
function of individual transcript variants in isolated cells 
from individuals with AAT deficiency will be the next 
step of our investigations.
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